Week 4 ELM 9: Synapses
Types of Synapse
Aim
- Transmit signal from one neuron to another.
Terminology
- Post-synaptic potential: EPSP (excitatory post-synaptic potential) or IPSP (inhibitory post-synaptic potential).
- Presynaptic neuron: The neuron sending the signal.
- Postsynaptic neuron: The neuron receiving the signal.
- Synaptic cleft: The space between the pre- and postsynaptic neurons.
- One-way transmission: Rectifying.
- Two-way transmission: Non-rectifying.
Electrical Synapses
- Gap junction: Direct connection between neurons.
- Direct transfer of ions: Allows for rapid communication.
- Non-rectifying: Signal can travel in both directions.
- Fast transmission: Virtually no synaptic delay.
- Signal often attenuated: Signal strength may decrease.
- Connexons: Made up of two connexons.
- Connexins: Each connexon consists of 6 connexins.
Drosophila Giant Fibre System
- Giant fibres: Axons of giant interneurons.
- Electrical synapses: Connect with leg and flight muscle motor neurons for rapid escape responses.
Chemical Synapses
- Synaptic delay: Time taken for the signal to cross the synapse; approximately 0.5−2ms.
Otto Loewi's Experiment (1921)
- Discovery of "Vagusstoff": Demonstrated chemical neurotransmission using frog hearts.
- Experiment: Stimulation of the vagus nerve in one heart, and transfer of the fluid to another heart, showed that a chemical substance (acetylcholine) was responsible for снижающейся heart rate.
Chemical Synapse - Vesicular Release
- Action potential: Arrives at the presynaptic terminal.
- Calcium influx: Voltage-gated Ca2+ channels open, allowing calcium to enter the presynaptic terminal.
- Vesicle fusion: Calcium allows vesicles to fuse with the presynaptic membrane and release neurotransmitter.
- Neurotransmitter binding: Neurotransmitter binds to receptors on the postsynaptic cell, causing ion channels to open or close.
- Postsynaptic potential: Excitatory (EPSP) or inhibitory (IPSP) postsynaptic potential is generated.
- Neurotransmitter removal: Neurotransmitter is removed by glial uptake or enzymatic degradation.
EM Morphology of Chemical Synapse
- Presynaptic terminal: Contains synaptic vesicles and mitochondria.
- Postsynaptic cell: Receives the signal.
- Synaptic vesicles: Store neurotransmitters.
- Mitochondria: Provide energy for synaptic transmission.
- Active zone: Region of the presynaptic membrane where vesicles fuse and release neurotransmitter; location of voltage-sensitive calcium channels (VSCC).
Vesicular Release: SNARE Proteins
- SNARE proteins: Synaptobrevin, SNAP-25, and syntaxin.
- Mechanism: SNARE proteins bind to each other, drawing the vesicle close to the membrane.
- Calcium sensing: Intracellular calcium concentrations rise, and calcium is sensed by synaptotagmin, a vesicle protein.
- Fusion: Vesicle fuses with the membrane, releasing neurotransmitter (e.g., ACh) into the synapse.
Quantal Release
- Steps of Synaptic Transmission:
- Neurotransmitters are synthesized and stored in vesicles.
- Action potential arrives at the presynaptic terminal.
- Voltage-gated Ca2+ channels open, allowing influx of Ca2+.
- Ca2+ allows vesicle fusion and neurotransmitter release.
- Neurotransmitter binds to receptors, causing channels to open (or close).
- Excitatory (or inhibitory) postsynaptic potential is generated.
- Neurotransmitter is removed by glial uptake (or enzymatic degradation).
- Vesicular membrane is retrieved from the plasma membrane.
Neurotransmitter Release
- Spontaneous Release: Occurs even without calcium.
- Evoked Release: Triggered by calcium influx.
- Quantal Nature: Neurotransmitter release is quantal, meaning it occurs in discrete packets.
- Quantum: Amount of transmitter per vesicle.
- MEPP: Miniature end-plate potential, the postsynaptic response to the release of a single quantum.
Quantal Content
- EPP: End-plate potential
- MEPP: Miniature end-plate potential
- Quantal content: =MEPPEPP
Miniature Postsynaptic Potentials (“Mini’s”)
- Spontaneous occurrence: Even in zero extracellular Ca2+.
- Amplitude: Multiples of a quantal unit.
- Cause: Release of one or a few quanta (vesicles).
- Effect of lowering extracellular Ca2+: EPSP amplitude decreases in a step-wise manner.
- Quantal analysis: AP-evoked EPSPs involve release of up to 200 quanta per AP.
- Quantal Content: Number of quanta released for one AP.
- Quantum content: Each quantum (packet/vesicle) contains several thousand molecules of ACh.
Vesicle Recycling
- Vesicle Cycle: A series of steps including docking, priming, calcium sensing, fusion, endocytosis, translocation, sorting, loading, storage, and mobilization.
Clathrin and Vesicle Recycling
- Clathrin: Protein involved in vesicle recycling.
- Clathrin coat: Formation of coated pits.
- Constant vesicle size: Helps maintain consistent neurotransmitter release.
- Constant number of vesicles: Ensures a readily available pool of vesicles.
- Constant size of terminal: Maintains structural integrity.
- Voltage-gated Ca2+ channel
- Acetylcholinesterase
- Nicotinic acetylcholine receptor
- SNARE proteins
Toxins Affecting Synaptic Transmission
- ω-agatoxin IVA: From the funnel web spider; blocks P/Q-type voltage-gated calcium channels.
- Used to subdue prey; helps determine which calcium channels are present in particular synapses.
- Botulinum toxin (Botox): Produced by Clostridium botulinum; cleaves SNARE proteins, stopping neurotransmitter release.
- Most deadly toxin known; causes muscle weakness and paralysis; used clinically for wrinkles, migraines, muscle spasms, and excessive sweating.
- ω-conotoxin MVIIC: From the magician cone snail; blocks N-type voltage-gated calcium channels.
- Used to paralyze prey; helps determine which types of voltage-sensitive calcium channels are present in a synapse. Synthetic version (ziconotide) treats pain.
- α-bungarotoxin: From the banded krait; blocks nicotinic acetylcholine receptors.
- Paralyzes prey; high affinity for the receptor makes it useful for probing the receptor's structure and function.
- Physostigmine (Eserine): From the Calabar bean; inhibits acetylcholinesterase, stopping the breakdown of acetylcholine.
- Treats myasthenia gravis (MG) by boosting acetylcholine concentrations; can reverse effects of toxins like curare.
- Myasthenia Gravis (MG): Autoimmune disease where nicotinic receptors are attacked by antibodies.
- Causes muscle weakness and drooping eyelids; treated with acetylcholinesterase inhibitors.